As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under the 340B Drug Pricing Program. HRSA also notified stakeholders that the secure pricing component of the 340B Office of Pharmacy Affairs Information System will be open for the submission of manufacturer pricing data in the first quarter of 2019.

The Department of Health and Human Services yesterday issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B program. The AHA said it was pleased that, in response to its lawsuit, the “final rule ensures that the implementation of the long-delayed” 340B ceiling price and civil monetary penalties policies will be effective Jan. 1. 

The AHA, Association of American Medical Colleges, America's Essential Hospitals, 340B Health and three hospital systems in September filed a lawsuit to force implementation of this rule in order to “shine needed light on drug pricing and to hold price-gouging drug companies accountable.”
 

Related News Articles

Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
The Department of Health and Human Services today announced prescription drug reforms that will become effective Oct. 1 originating from the Health Data,…
Headline
The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program.“It is a ‘solution’ in search of a…
Headline
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…
Headline
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…